JP2020530293A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020530293A5 JP2020530293A5 JP2020506964A JP2020506964A JP2020530293A5 JP 2020530293 A5 JP2020530293 A5 JP 2020530293A5 JP 2020506964 A JP2020506964 A JP 2020506964A JP 2020506964 A JP2020506964 A JP 2020506964A JP 2020530293 A5 JP2020530293 A5 JP 2020530293A5
- Authority
- JP
- Japan
- Prior art keywords
- place
- seq
- sequence
- ala
- polypeptide comprises
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims description 387
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 387
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 387
- 239000000539 dimer Substances 0.000 claims description 45
- 108020001507 fusion proteins Proteins 0.000 claims description 9
- 102000037865 fusion proteins Human genes 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 102000007238 Transferrin Receptors Human genes 0.000 claims description 7
- 108010033576 Transferrin Receptors Proteins 0.000 claims description 7
- 108091033319 polynucleotide Proteins 0.000 claims description 7
- 102000040430 polynucleotide Human genes 0.000 claims description 7
- 239000002157 polynucleotide Substances 0.000 claims description 7
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 claims description 6
- 230000008499 blood brain barrier function Effects 0.000 claims description 6
- 210000001218 blood-brain barrier Anatomy 0.000 claims description 6
- 210000003038 endothelium Anatomy 0.000 claims description 6
- 239000012634 fragment Substances 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 239000000427 antigen Substances 0.000 claims description 4
- 102000036639 antigens Human genes 0.000 claims description 4
- 108091007433 antigens Proteins 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 210000004899 c-terminal region Anatomy 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 150000007523 nucleic acids Chemical group 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 230000031998 transcytosis Effects 0.000 claims description 2
- 230000000447 dimerizing effect Effects 0.000 claims 1
- 230000003511 endothelial effect Effects 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762543658P | 2017-08-10 | 2017-08-10 | |
| US62/543,658 | 2017-08-10 | ||
| US201762583314P | 2017-11-08 | 2017-11-08 | |
| US62/583,314 | 2017-11-08 | ||
| PCT/US2018/018371 WO2018152326A1 (en) | 2017-02-17 | 2018-02-15 | Engineered transferrin receptor binding polypeptides |
| USPCT/US2018/018371 | 2018-02-15 | ||
| PCT/US2018/046199 WO2019032955A1 (en) | 2017-08-10 | 2018-08-10 | MODIFIED TRANSFERRIN RECEPTOR BINDING POLYPEPTIDES |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020530293A JP2020530293A (ja) | 2020-10-22 |
| JP2020530293A5 true JP2020530293A5 (enExample) | 2021-09-16 |
| JP7280241B2 JP7280241B2 (ja) | 2023-05-23 |
Family
ID=65272509
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020507090A Pending JP2020530465A (ja) | 2017-08-10 | 2018-08-10 | トランスフェリン受容体結合タンパク質を使用するための、親和性に基づく方法 |
| JP2020506964A Active JP7280241B2 (ja) | 2017-08-10 | 2018-08-10 | 操作されたトランスフェリン受容体結合ポリペプチド |
| JP2023107814A Pending JP2023123757A (ja) | 2017-08-10 | 2023-06-30 | トランスフェリン受容体結合タンパク質を使用するための、親和性に基づく方法 |
| JP2025090730A Pending JP2025120209A (ja) | 2017-08-10 | 2025-05-30 | トランスフェリン受容体結合タンパク質を使用するための、親和性に基づく方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020507090A Pending JP2020530465A (ja) | 2017-08-10 | 2018-08-10 | トランスフェリン受容体結合タンパク質を使用するための、親和性に基づく方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023107814A Pending JP2023123757A (ja) | 2017-08-10 | 2023-06-30 | トランスフェリン受容体結合タンパク質を使用するための、親和性に基づく方法 |
| JP2025090730A Pending JP2025120209A (ja) | 2017-08-10 | 2025-05-30 | トランスフェリン受容体結合タンパク質を使用するための、親和性に基づく方法 |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US20200369746A1 (enExample) |
| EP (2) | EP3665194A4 (enExample) |
| JP (4) | JP2020530465A (enExample) |
| CN (2) | CN111094336A (enExample) |
| CA (2) | CA3072051A1 (enExample) |
| DK (1) | DK3665192T5 (enExample) |
| ES (1) | ES2956062T3 (enExample) |
| FI (1) | FI3665192T3 (enExample) |
| HR (1) | HRP20231118T1 (enExample) |
| HU (1) | HUE063021T2 (enExample) |
| LT (1) | LT3665192T (enExample) |
| MD (1) | MD3665192T2 (enExample) |
| PL (1) | PL3665192T3 (enExample) |
| PT (1) | PT3665192T (enExample) |
| RS (1) | RS64584B1 (enExample) |
| SI (1) | SI3665192T1 (enExample) |
| SM (1) | SMT202300347T1 (enExample) |
| TW (1) | TWI821197B (enExample) |
| WO (2) | WO2019032955A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3583120T (pt) | 2017-02-17 | 2022-12-15 | Denali Therapeutics Inc | Polipeptídeos de ligação ao recetor de transferrina manipulados |
| BR112020005271A2 (pt) | 2017-10-02 | 2020-09-15 | Denali Therapeutics Inc. | proteína, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, método para produção de um polipeptídeo, métodos de tratamento de um distúrbio, de diminuição do acúmulo, de monitoramento, de transporte de um agente e de tratamento de um lsd e composição farmacêutica |
| JP2021534220A (ja) * | 2018-08-22 | 2021-12-09 | デナリ セラピューティクス インコーポレイテッドDenali Therapeutics Inc. | 抗ｈｅｒ２ポリペプチド及びそれらの使用の方法 |
| AU2020226754A1 (en) | 2019-02-20 | 2021-09-16 | Denali Therapeutics Inc. | Anti-TREM2 antibodies and methods of use thereof |
| IL293994A (en) | 2019-12-23 | 2022-08-01 | Denali Therapeutics Inc | Progranulin variants, compositions comprising same and uses thereof |
| CN115279790A (zh) * | 2020-01-13 | 2022-11-01 | 戴纳立制药公司 | 抗trem2抗体和其使用方法 |
| CA3170338A1 (en) * | 2020-02-19 | 2021-08-26 | Denali Therapeutics Inc. | Engineered anti-her2 bispecific proteins |
| PE20231931A1 (es) | 2020-10-14 | 2023-12-01 | Denali Therapeutics Inc | Proteinas de fusion que comprenden enzimas sulfoglucosamina sulfohidrolasa y metodos de estas |
| US11827702B2 (en) | 2021-09-01 | 2023-11-28 | Biogen Ma Inc. | Anti-transferrin receptor antibodies and uses thereof |
| CA3242212A1 (en) * | 2021-12-31 | 2023-07-06 | Imnewrun Inc | Blood-brain barrier permeable fusion protein and uses thereof |
| KR20250048010A (ko) | 2022-07-29 | 2025-04-07 | 리제너론 파마슈티칼스 인코포레이티드 | 변형된 트랜스페린 수용체 좌위를 포함하는 비-인간 동물 |
| JP2025528052A (ja) | 2022-07-29 | 2025-08-26 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 脳及び筋肉へのトランスフェリン受容体（ｔｆｒ）媒介送達のための組成物及び方法 |
| CN120865438A (zh) | 2022-07-29 | 2025-10-31 | 瑞泽恩制药公司 | 重新靶向转铁蛋白受体1的病毒颗粒 |
| US20240052051A1 (en) | 2022-07-29 | 2024-02-15 | Regeneron Pharmaceuticals, Inc. | Anti-tfr:payload fusions and methods of use thereof |
| WO2024130116A2 (en) * | 2022-12-16 | 2024-06-20 | Denali Therapeutics Inc. | Methods and compositions related to engineered transferrin receptor‑binding molecules |
| US20250049896A1 (en) | 2023-07-28 | 2025-02-13 | Regeneron Pharmaceuticals, Inc. | Anti-tfr:acid sphingomyelinase for treatment of acid sphingomyelinase deficiency |
| WO2025029657A2 (en) | 2023-07-28 | 2025-02-06 | Regeneron Pharmaceuticals, Inc. | Anti-tfr:gaa and anti-cd63:gaa insertion for treatment of pompe disease |
| WO2025137213A1 (en) | 2023-12-20 | 2025-06-26 | Denali Therapeutics Inc. | Fusion proteins comprising acid alpha-glucosidase enzymes and methods thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1212365A2 (en) * | 1999-08-30 | 2002-06-12 | New York University School Of Medicine | Crystal structures of domains of receptor protein tyrosine kinases and their ligands |
| CN101516907B (zh) * | 2006-08-01 | 2015-08-26 | 皮里斯股份公司 | 泪液脂质运载蛋白的突变蛋白及其获得方法 |
| EA034333B1 (ru) * | 2010-11-30 | 2020-01-29 | Дженентек, Инк. | Варианты антитела для переноса соединения через гематоэнцефалический барьер |
| EA201892619A1 (ru) * | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| CA2879496C (en) * | 2012-08-29 | 2024-01-09 | F. Hoffmann-La Roche Ag | Blood brain barrier shuttle |
| EP4324480A3 (en) * | 2013-05-20 | 2024-05-08 | F. Hoffmann-La Roche AG | Anti-transferrin receptor antibodies and methods of use |
| BR112016015589A2 (pt) * | 2014-01-06 | 2017-10-31 | Hoffmann La Roche | módulos de trânsito monovalentes para a barreira hematoencefálica |
| CN113621050A (zh) * | 2014-05-22 | 2021-11-09 | 皮里斯制药有限公司 | 新型特异性结合多肽及其用途 |
| CA2967830A1 (en) * | 2014-11-14 | 2016-05-19 | Ossianix, Inc. | Tfr selective binding compounds and related methods |
| EP3221362B1 (en) * | 2014-11-19 | 2019-07-24 | F.Hoffmann-La Roche Ag | Anti-transferrin receptor antibodies and methods of use |
| EP3221361B1 (en) * | 2014-11-19 | 2021-04-21 | Genentech, Inc. | Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use |
| IL302486A (en) * | 2015-06-24 | 2023-06-01 | Hoffmann La Roche | Antibodies against the transnephrine receptor with adapted affinity |
| AR106189A1 (es) * | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
| US10457717B2 (en) * | 2017-02-17 | 2019-10-29 | Denali Therapeutics Inc. | Engineered polypeptides |
-
2018
- 2018-08-10 JP JP2020507090A patent/JP2020530465A/ja active Pending
- 2018-08-10 EP EP18843180.3A patent/EP3665194A4/en active Pending
- 2018-08-10 MD MDE20200637T patent/MD3665192T2/ro unknown
- 2018-08-10 CA CA3072051A patent/CA3072051A1/en active Pending
- 2018-08-10 SM SM20230347T patent/SMT202300347T1/it unknown
- 2018-08-10 JP JP2020506964A patent/JP7280241B2/ja active Active
- 2018-08-10 PL PL18756531.2T patent/PL3665192T3/pl unknown
- 2018-08-10 FI FIEP18756531.2T patent/FI3665192T3/fi active
- 2018-08-10 LT LTEPPCT/US2018/046199T patent/LT3665192T/lt unknown
- 2018-08-10 TW TW107128067A patent/TWI821197B/zh active
- 2018-08-10 HU HUE18756531A patent/HUE063021T2/hu unknown
- 2018-08-10 EP EP18756531.2A patent/EP3665192B1/en active Active
- 2018-08-10 CN CN201880053177.4A patent/CN111094336A/zh active Pending
- 2018-08-10 HR HRP20231118TT patent/HRP20231118T1/hr unknown
- 2018-08-10 ES ES18756531T patent/ES2956062T3/es active Active
- 2018-08-10 WO PCT/US2018/046199 patent/WO2019032955A1/en not_active Ceased
- 2018-08-10 WO PCT/US2018/046337 patent/WO2019033046A1/en not_active Ceased
- 2018-08-10 PT PT187565312T patent/PT3665192T/pt unknown
- 2018-08-10 DK DK18756531.2T patent/DK3665192T5/da active
- 2018-08-10 RS RS20230817A patent/RS64584B1/sr unknown
- 2018-08-10 SI SI201830986T patent/SI3665192T1/sl unknown
- 2018-08-10 CA CA3072035A patent/CA3072035A1/en active Pending
- 2018-08-10 CN CN201880063660.0A patent/CN111148757B/zh active Active
-
2020
- 2020-02-05 US US16/782,669 patent/US20200369746A1/en not_active Abandoned
- 2020-02-05 US US16/782,984 patent/US20200289627A1/en not_active Abandoned
-
2023
- 2023-02-08 US US18/166,223 patent/US20230381286A1/en active Pending
- 2023-06-30 JP JP2023107814A patent/JP2023123757A/ja active Pending
- 2023-09-08 US US18/464,025 patent/US20240024432A1/en not_active Abandoned
-
2025
- 2025-05-30 JP JP2025090730A patent/JP2025120209A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020530293A5 (enExample) | ||
| FI3665192T3 (fi) | Muunneltuja transferriinireseptoria sitovia polypeptidejä | |
| JP2020186248A5 (enExample) | ||
| JP2019521643A5 (enExample) | ||
| JP2011501951A5 (enExample) | ||
| RU2015129640A (ru) | Связанные дисульфидом мультивалентные многофункциональные белки, содержащие молекулы гкгс класса 1 | |
| JP2020500015A5 (enExample) | ||
| JP2019536440A5 (enExample) | ||
| AU2012332263A1 (en) | Low density lipoprotein-related protein 6 (LRP6) - half life extender constructs | |
| RU2015152077A (ru) | Тримерные антигенсвязывающие молекулы | |
| RU2017144098A (ru) | Гетеродимеризованный полипептид | |
| JP2014510518A5 (enExample) | ||
| KR20140067944A (ko) | 항체 중쇄불변부위의 이종이중체 고효율 형성을 유도하는 ch3 도메인 변이체 쌍, 이의 제조방법, 및 용도 | |
| JP2013507115A (ja) | 「終末糖化産物受容体」への結合のためのポリペプチド、さらにはそれを含む組成物及び方法 | |
| JP2018519803A5 (enExample) | ||
| JP2010502183A5 (enExample) | ||
| JP6143133B2 (ja) | ヒト化抗ヒト上皮成長因子受容体抗体、そのコード遺伝子及びその応用 | |
| JP2019506140A5 (enExample) | ||
| JP2017509323A5 (enExample) | ||
| Lu et al. | Acquired antagonistic activity of a bispecific diabody directed against two different epitopes on vascular endothelial growth factor receptor 2 | |
| JP2021512159A5 (enExample) | ||
| RU2018141360A (ru) | Contorsbody - одноцепочечный связывающий мишень агент | |
| JP2015504052A5 (enExample) | ||
| HRP20221142T1 (hr) | Modificirana igg protutijela koja se vežu na transformirajući faktor rasta beta1 s visokim afinitetom, avidnošću i specifičnošću | |
| CN118420750A (zh) | 抗猴痘病毒a35r蛋白的单克隆抗体8d7或其抗体片段 |